Connect your AI

Arrowhead Research ARWR Equity in earnings (losses) of equity method investees

Equity in earnings (losses) of equity method investees at other companies

BridgeBio PharmaBBIO

——

Other financials

Income statement

Revenue$73.7M-86.4%

Operating income-$141.3M-137%

Net income-$132.7M-136%

EPS (diluted)-$0.93-134%

Balance sheet

Cash & equivalents$188.5M+1.5%

Total debt$107.9M-5.6%

Total equity$614.0M-10.1%

Total assets$2.3B+44.2%

Cash flow

Operating cash flow$84.4M-81.6%

CapEx$2.6M-51.6%

Free cash flow$81.9M-82.0%

Valuation

Market cap$11.52B+402%

Enterprise value$11.44B+418%

P/S18.5×+14.3×

Profitability

Operating margin-35.7%+63.6pp

Net margin-48.4%+240pp

FCF margin1.8%+0.9pp

Returns & leverage

Return on equity-46.4%+341pp

Debt / equity0.2×0.0×

Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's equity in earnings (losses) of equity method investees.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arrowhead Research's equity in earnings (losses) of equity method investees?: Arrowhead Research (ARWR) reported equity in earnings (losses) of equity method investees of -$6.72M in Q1 2026.